InflaRx NV (IFRX)
1.72
+0.06
(+3.61%)
USD |
NASDAQ |
Apr 21, 13:39
InflaRx EPS Diluted (Quarterly) : -0.2115 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| CDT Equity, Inc. | -231.44 |
| LENZ Therapeutics, Inc. | -1.155 |
| Liminatus Pharma, Inc. | -0.3018 |
| Oruka Therapeutics, Inc. | -0.5436 |
| Maze Therapeutics, Inc. | -0.7007 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.33M |
| Revenue (Quarterly) | 0.0278M |
| Total Expenses (Quarterly) | 14.36M |
| Enterprise Value | 68.69M |
| Gross Profit Margin (Quarterly) | -320.9% |
| Profit Margin (Quarterly) | -51.54K% |
| Earnings Yield | -53.28% |
| Normalized Earnings Yield | -51.63 |